



(51) International Patent Classification:

A61K 31/395 (2006.01) A61K 31/16 (2006.01)
A61K 31/4192 (2006.01) A61K 31/33 (2006.01)

(21) International Application Number:

PCT/US2024/013767

(22) International Filing Date:

31 January 2024 (31.01.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/482,486 31 January 2023 (31.01.2023) US
63/606,161 05 December 2023 (05.12.2023) US

(71) Applicant: YALE UNIVERSITY [US/US]; Two Whitney Avenue, New Haven, Connecticut 06510 (US).

(72) Inventors: SPIEGEL, David; c/o Yale Ventures, 433 Temple Street, New Haven, Connecticut 06511 (US). DER-AMON, Edward; c/o Yale Ventures, 433 Temple Street, New Haven, Connecticut 06511 (US). MCDONALD,

David; c/o Yale Ventures, 433 Temple Street, New Haven, Connecticut 06511 (US).

(74) Agent: SILVA, Domingos, J. et al.; Centre Square West, 1500 Market Street, 38th Floor, Philadelphia, Pennsylvania 19102-2186 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) Title: COMPOUNDS AND METHODS FOR TREATING, AMELIORATING, OR PREVENTING ARTHRITIS




FIG. 1

AA Construction bifonctionnelle
BB Endocytose
CC Hépatocyte
DD Cible
EE Protéine extracellulaire ciblant un ligand
FF Lieur
GG Fraction de liaison de récepteur cellulaire (CRBM)
HH Récepteur cellulaire (par exemple, ASGPR)
II Dégradation

(57) Abstract: The disclosure describes compounds, which in non-limiting aspects contain an asialoglycoprotein receptor (ASGPR) binding moiety and an anti-CCP (anti-cyclic citrullinated peptide binding moiety). The compounds are useful in preventing, treating, and/or ameliorating various types of arthritis, including rheumatoid arthritis (RA), in a subject when administered in therapeutically effective amounts.

[Continued on next page]

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

07 November 2024 (07.11.2024)